Access brought to you by: LOCKSS

Liver Conditions

Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3
SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results
Sebelipase Alfa Normalizes ALT and Multiple other Disease-Related Abnormalities in Patients with LAL-D
Terlipressin and Albumin Combination Therapy Improves Renal Function in HRS-1
Direct-Acting Antiviral Therapy Produces High SVR12 in HCV GT-1 Cirrhotic Patients Regardless of Baseline Characteristics
Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF
100% SVR with Ledipasvir/Sofosbuvir Plus Ribavirin in Patients with HCV GT-1 Failing Prior Therapy
High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection
Interferon- and RBV-Free Treatment with LDV and SOF is Efficacious in Patients Coinfected with HCV and HIV

Pages